J. Ferlay, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

L. Rahib, Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States, Cancer Res, vol.74, pp.2913-2921, 2014.

N. J. Nowak, Genome-wide aberrations in pancreatic adenocarcinoma, Cancer Genet. Cytogenet, vol.161, pp.36-50, 2005.

M. Büchler, A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer, Cancer, vol.68, pp.1507-1512, 1991.

H. Friess, M. Büchler, M. Krüger, and H. G. Beger, Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin, Pancreas, vol.7, pp.516-521, 1992.

A. L. Coveler, J. M. Herman, D. M. Simeone, and E. G. Chiorean, Localized Pancreatic Cancer: Multidisciplinary Management

W. Hartwig, J. Werner, and M. W. Büchler, Prognosis of resected pancreatic cancer: is the refined resection margin status dispensable?, Langenbecks Arch. Surg, vol.397, pp.859-860, 2012.

C. Louvet and P. A. Philip, Accomplishments in 2007 in the Treatment of Metastatic Pancreatic Cancer, Gastrointest. Cancer Res. GCR, vol.2, pp.37-41, 2008.

W. Greenhalf, Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial, JNCI J. Natl. Cancer Inst, vol.106, 2014.

S. N. Badiyan, J. K. Molitoris, M. D. Chuong, W. F. Regine, and A. Kaiser, The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings, Surg. Oncol. Clin. N. Am, vol.26, pp.431-453, 2017.

H. A. Burris, Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial, J. Clin. Oncol, vol.15, pp.2403-2413, 1997.

C. Thierry, FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

, Engl. J. Med, vol.9, 2011.

V. Hoff and D. D. , Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus ! 24

. Gemcitabine, N. Engl. J. Med, vol.369, pp.1691-1703, 2013.

P. Hammel, Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial, JAMA, vol.315, p.1844, 2016.

R. Siegel, J. Ma, Z. Zou, and A. Jemal, Cancer statistics, CA. Cancer J. Clin, vol.64, pp.9-29, 2014.

M. P. Hidalgo and . Cancer, N. Engl. J. Med, vol.362, pp.1605-1617, 2010.

M. Erkan, The role of stroma in pancreatic cancer: diagnostic and therapeutic implications, Nat. Rev. Gastroenterol. Hepatol, vol.9, pp.454-467, 2012.

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, pp.646-674, 2011.

M. Erkan, The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma, Clin. Gastroenterol. Hepatol, vol.6, pp.1155-1161, 2008.

A. Costa, Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer, Cancer Cell, vol.33, pp.463-479, 2018.

C. Neuzillet, Inter-and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma: CAF heterogeneity in pancreatic cancer, J. Pathol, 2019.

D. Öhlund, Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer, J. Exp. Med. jem, p.20162024, 2017.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting, Immunity, vol.21, pp.137-148, 2004.

J. Galon and . Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, pp.1960-1964, 2006.

C. G. Clemente, Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, vol.77, pp.1303-1310, 1996.

R. Salgado, The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group, Ann. Oncol. Off. J. Eur. Soc, 2014.

, Med. Oncol, vol.26, pp.259-271, 2015.

Y. Geng, Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-! 25

, Analysis. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol, vol.37, pp.1560-1571, 2015.

L. Zhang, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

. Engl, J. Med, vol.348, pp.203-213, 2003.

F. Pagès, Effector memory T cells, early metastasis, and survival in colorectal cancer

. Engl, J. Med, vol.353, pp.2654-2666, 2005.

X. Yuan, Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses Tcell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner

, Clin. Immunol. Orlando Fla, vol.134, pp.277-288, 2010.

S. Hinz, Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer, Cancer Res, vol.67, pp.8344-8350, 2007.

Y. Jiang, FOXP3+ Lymphocyte Density in Pancreatic Cancer Correlates with Lymph Node Metastasis, PLoS ONE, vol.9, p.106741, 2014.

G. J. Bates, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.5373-5380, 2006.

J. Fu, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients, Gastroenterology, vol.132, pp.2328-2339, 2007.

Q. Gao, Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma, Ann. Surg. Oncol, vol.19, pp.455-466, 2012.

H. Kim, The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer, J. Surg. Oncol, vol.104, pp.728-733, 2011.

R. P. Petersen, Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients, Cancer, vol.107, pp.2866-2872, 2006.

F. A. Sinicrope, Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma, Gastroenterology, vol.137, pp.1270-1279, 2009.

M. J. Gooden, G. H. De-bock, N. Leffers, T. Daemen, and H. W. Nijman, The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

, Br. J. Cancer, vol.105, pp.93-103, 2011.

M. B. Slidell, Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large

, Ann. Surg. Oncol, vol.15, pp.165-174, 2008.

C. R. Ferrone, Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2897-2902, 2006.

S. K. Kamarajah, W. R. Burns, T. L. Frankel, C. S. Cho, and H. Nathan,

, American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis

, Ann. Surg. Oncol, vol.24, pp.2023-2030, 2017.

U. M. Mahajan, Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma, Gastroenterology, vol.155, pp.1625-1639, 2018.

V. Tjomsland, The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma, Clin. Dev. Immunol, p.212810, 2011.

M. Wartenberg, Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma, Oncotarget, vol.6, 2015.

Y. Ino, Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer, Br. J. Cancer, vol.108, pp.914-923, 2013.

R. C. Miksch, Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer, Cancers, vol.11, 2019.

S. B. Dreyer, Defining the molecular pathology of pancreatic body and tail adenocarcinoma: Molecular pathology of pancreatic body and tail adenocarcinoma, Br. J. Surg, vol.105, pp.183-191, 2018.

H. K. Hwang, Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/ activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer

, Oncol. Lett, vol.12, pp.4477-4484, 2016.

C. Ginestier, Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers, Am. J. Pathol, vol.161, pp.1223-1233, 2002.

J. Fléjou, Classification OMS 2010 des tumeurs digestives : la quatrième édition, Ann. Pathol, vol.31, pp.27-31, 2011.

J. Kleeff, Pancreatic cancer, Nat. Rev. Dis. Primer, vol.2, p.16022, 2016.

N. Waddell, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, vol.518, pp.495-501, 2015.

E. A. Collisson, Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy, Nat. Med, vol.17, pp.500-503, 2011.

P. Bailey, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, vol.531, pp.47-52, 2016.

R. A. Moffitt, Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat. Genet, vol.47, pp.1168-1178, 2015.

M. F. Brennan, M. W. Kattan, D. Klimstra, and K. Conlon, Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas, Ann. Surg, vol.240, pp.293-298, 2004.

A. Maitra, R. H. Hruban, and . Pancreatic-cancer, Annu. Rev. Pathol, vol.3, pp.157-188, 2008.

A. A. Rucki and L. Zheng, Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies, World J. Gastroenterol, vol.20, pp.2237-2246, 2014.

G. C. Chu, A. C. Kimmelman, A. F. Hezel, and R. A. Depinho, Stromal biology of pancreatic cancer, J. Cell. Biochem, vol.101, pp.887-907, 2007.

C. Feig, The Pancreas Cancer Microenvironment, Clin. Cancer Res, vol.18, pp.4266-4276, 2012.

M. Waghray, M. Yalamanchili, M. P. Di-magliano, and D. M. Simeone, Deciphering the role of stroma in pancreatic cancer, Curr. Opin. Gastroenterol, vol.29, pp.537-543, 2013.

C. Denkert, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.105-113, 2010.

H. R. Ali, Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.25, pp.1536-1543, 2014.

S. L. Topalian, Durable Tumor Remission, and Long-Term Safety in Patients ! 28, Survival

, With Advanced Melanoma Receiving Nivolumab, J. Clin. Oncol, vol.32, pp.1020-1030, 2014.

P. A. Bunn and . Karnofsky-award, A Lung Cancer Journey, vol.35, pp.243-252, 1973.

S. Verma, Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

, J. Med, vol.367, pp.1783-1791, 2012.

M. Hewish, C. J. Lord, S. A. Martin, D. Cunningham, and A. Ashworth, Mismatch repair deficient colorectal cancer in the era of personalized treatment, Nat. Rev. Clin. Oncol, vol.7, pp.197-208, 2010.

R. A. Skelton, A. Javed, L. Zheng, and J. He, Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors, J. Surg. Oncol, vol.116, pp.55-62, 2017.

C. S. Verbeke, Resection margins and R1 rates in pancreatic cancer -are we there yet?, Histopathology, vol.52, pp.787-796, 2008.

C. S. Verbeke and K. V. Menon, Redefining resection margin status in pancreatic cancer, HPB, vol.11, pp.282-289, 2009.

S. Romagnani and . Subpopulations, Chemical Immunology and Allergy, vol.100, pp.155-164, 2014.

N. Tewari, The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays, BMC Cancer, vol.13, p.436, 2013.

S. Karakhanova, Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma, Br. J. Cancer, vol.112, pp.1027-1036, 2015.

K. Tahkola, High immune cell score predicts improved survival in pancreatic cancer, Virchows Arch. Int. J. Pathol, vol.472, pp.653-665, 2018.

R. Nejati, Prognostic Significance of Tumor Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy, Pancreas, vol.46, pp.1180-1187, 2017.

E. Ryschich, Control of T-Cell-Mediated Immune Response by HLA Class I in Human Pancreatic Carcinoma

B. C. Özdemir, Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces ! 29

, Immunosuppression and Accelerates Pancreas Cancer with Diminished Survival, Cancer Cell, vol.25, pp.719-734, 2014.

T. Shan, Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism, Oncol. Rep, vol.37, pp.1971-1979, 2017.

R. A. Battaglia, S. Delic, H. Herrmann, and N. T. Snider, Vimentin on the move: new developments in cell migration, F1000Research, vol.7, 2018.

R. Kalluri, The biology and function of fibroblasts in cancer, Nat. Rev. Cancer, vol.16, pp.582-598, 2016.

M. A. Postow, M. K. Callahan, and J. D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy, J. Clin. Oncol, vol.33, pp.1974-1982, 2015.

D. J. Birnbaum, Prognostic value of PDL1 expression in pancreatic cancer, Oncotarget, vol.7, pp.71198-71210, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01765421

F. Penault-llorca and N. Radosevic-robin, Ki67 assessment in breast cancer: an update, Pathology (Phila.), vol.49, p.30, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01675161